87 related articles for article (PubMed ID: 10022534)
21. Collagen and major histocompatibility class II expression in mesenchymal cells from CIITA hypomorphic mice.
Xu Y; McDonald J; Perloff E; Butticè G; Schreiber BM; Smith BD
Mol Immunol; 2007 Mar; 44(7):1709-21. PubMed ID: 16982097
[TBL] [Abstract][Full Text] [Related]
22. Disruption of intracerebral progression of C6 rat glioblastoma by in vivo treatment with anti-CD44 monoclonal antibody.
Breyer R; Hussein S; Radu DL; Pütz KM; Gunia S; Hecker H; Samii M; Walter GF; Stan AC
J Neurosurg; 2000 Jan; 92(1):140-9. PubMed ID: 10616093
[TBL] [Abstract][Full Text] [Related]
23. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
[TBL] [Abstract][Full Text] [Related]
24. Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells.
Sartoris S; Tosi G; De Lerma Barbaro A; Cestari T; Accolla RS
Eur J Immunol; 1996 Oct; 26(10):2456-60. PubMed ID: 8898960
[TBL] [Abstract][Full Text] [Related]
25. Prolonged survival of rats with intracranial C6 gliomas by treatment with TGF-beta antisense gene.
Liau LM; Fakhrai H; Black KL
Neurol Res; 1998 Dec; 20(8):742-7. PubMed ID: 9864741
[TBL] [Abstract][Full Text] [Related]
26. Site-specific immune response to implanted gliomas.
Proescholdt MA; Merrill MJ; Ikejiri B; Walbridge S; Akbasak A; Jacobson S; Oldfield EH
J Neurosurg; 2001 Dec; 95(6):1012-9. PubMed ID: 11765816
[TBL] [Abstract][Full Text] [Related]
27. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA.
Muhlethaler-Mottet A; Otten LA; Steimle V; Mach B
EMBO J; 1997 May; 16(10):2851-60. PubMed ID: 9184229
[TBL] [Abstract][Full Text] [Related]
28. The N-terminal domain of NLRC5 confers transcriptional activity for MHC class I and II gene expression.
Neerincx A; Jakobshagen K; Utermöhlen O; Büning H; Steimle V; Kufer TA
J Immunol; 2014 Sep; 193(6):3090-100. PubMed ID: 25127861
[TBL] [Abstract][Full Text] [Related]
29. [Hydrogen sulfide stimulates the development of rat glioblastoma].
Li ZY; Liu SC; Xu PJ; Yang Z; Zhang T
Zhonghua Zhong Liu Za Zhi; 2012 Apr; 34(4):254-8. PubMed ID: 22781035
[TBL] [Abstract][Full Text] [Related]
30. Modified immunoregulation associated with interferon-gamma treatment of rat glioma.
Oshiro S; Liu Y; Fukushima T; Asotra K; Black KL
Neurol Res; 2001 Jun; 23(4):359-66. PubMed ID: 11428516
[TBL] [Abstract][Full Text] [Related]
31. Malignant Glioma Therapy by Vaccination with Irradiated C6 Cell-Derived Microvesicles Promotes an Antitumoral Immune Response.
Pineda B; Sánchez García FJ; Olascoaga NK; Pérez de la Cruz V; Salazar A; Moreno-Jiménez S; Hernández Pedro N; Márquez-Navarro A; Ortiz Plata A; Sotelo J
Mol Ther; 2019 Sep; 27(9):1612-1620. PubMed ID: 31204210
[TBL] [Abstract][Full Text] [Related]
32. Differential expression of MHC class II molecules in highly metastatic breast cancer cells is mediated by the regulation of the CIITA transcription Implication of CIITA in tumor and metastasis development.
Shi B; Vinyals A; Alia P; Broceño C; Chen F; Adrover M; Gelpi C; Price JE; Fabra A
Int J Biochem Cell Biol; 2006; 38(4):544-62. PubMed ID: 16343978
[TBL] [Abstract][Full Text] [Related]
33. Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells.
Meazza R; Comes A; Orengo AM; Ferrini S; Accolla RS
Eur J Immunol; 2003 May; 33(5):1183-92. PubMed ID: 12731043
[TBL] [Abstract][Full Text] [Related]
34. Revisiting the specificity of the MHC class II transactivator CIITA in vivo.
Otten LA; Leibundgut-Landmann S; Huarte J; Kos-Braun IC; Lavanchy C; Barras E; Borisch B; Steimle V; Acha-Orbea H; Reith W
Eur J Immunol; 2006 Jun; 36(6):1548-58. PubMed ID: 16703565
[TBL] [Abstract][Full Text] [Related]
35. Reduced IL-4-, lipopolysaccharide-, and IFN-gamma-induced MHC class II expression in mice lacking class II transactivator due to targeted deletion of the GTP-binding domain.
Itoh-Lindstrom Y; Piskurich JF; Felix NJ; Wang Y; Brickey WJ; Platt JL; Koller BH; Ting JP
J Immunol; 1999 Sep; 163(5):2425-31. PubMed ID: 10452977
[TBL] [Abstract][Full Text] [Related]
36. pRB is required for interferon-gamma-induction of the MHC class II abeta gene.
Zhu X; Pattenden S; Bremner R
Oncogene; 1999 Sep; 18(35):4940-7. PubMed ID: 10490828
[TBL] [Abstract][Full Text] [Related]
37. Complement contributes to the rejection of complete and class I major histocompatibility complex--incompatible cardiac allografts.
Qian Z; Jakobs FM; Pfaff-Amesse T; Sanfilippo F; Baldwin WM
J Heart Lung Transplant; 1998 May; 17(5):470-8. PubMed ID: 9628565
[TBL] [Abstract][Full Text] [Related]
38. Regulation of the class II and class I MHC pathways in human THP-1 monocytic cells by interleukin-27.
Feng XM; Liu N; Yang SG; Hu LY; Chen XL; Fang ZH; Ren Q; Lu SH; Liu B; Han ZC
Biochem Biophys Res Commun; 2008 Mar; 367(3):553-9. PubMed ID: 18178151
[TBL] [Abstract][Full Text] [Related]
39. Introduction of exogenous class II trans-activator in MHC class II-deficient ABI fibroblasts results in incomplete rescue of MHC class II antigen expression.
Peijnenburg A; Gobin SJ; van Eggermond MC; Godthelp BC; van Graafeiland N; van den Elsen PJ
J Immunol; 1997 Sep; 159(6):2720-7. PubMed ID: 9300692
[TBL] [Abstract][Full Text] [Related]
40. The MHC class II transactivator (CIITA) mRNA stability is critical for the HLA class II gene expression in myelomonocytic cells.
De Lerma Barbaro A; Procopio FA; Mortara L; Tosi G; Accolla RS
Eur J Immunol; 2005 Feb; 35(2):603-11. PubMed ID: 15627980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
